Acumen Pharmaceuticals Presents Late-Breaker Phase 1 Updates Exploring Novel Target Engagement, Dosing Regimen and Safety Findings for ACU193 in Early Alzheimer's Disease at the 16th Annual Clinical Trials on Alzheimer's Disease -October 27, 2023 at 09:26 am EDT
- Acumen presented data exploring target engagement modeling of ACU193, the first clinical-stage amyloid beta oligomer -targeting antibody, to inform dose selection, plus further analyses of...
Source: marketscreener.com